University Medical Center Groningen

Site:	University Medical Center Groningen
Address:
City:	Groningen
State:
Zip:	9713 GZ
Country:	Netherlands

Phase	Trial	Trial Status [asc]	Site Status	Drug	NCT#
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
3	Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST	Active, not recruiting	Closed	Imatinib	NCT02413736
1	A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients	Completed	Closed	Imatinib + BYL719	NCT01735968
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active, not recruiting	Bezuclastinib plus Sunitinib	NCT05208047
3	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Recruiting	Active	Ripretinib	NCT05734105
	GIST: Assessment of Tumor Mutations and TKI Plasma Exposure	Recruiting	Active	Imatinib + Sunitinib + Regorafenib	NCT02331914